Exposure assessment of epidermal growth factor to various tissues in mice after intravenous and subcutaneous administration. (10th August 2015)

• Record Type: Journal Article
• Authors: Lee, Jong Bong; Shin, Beomsoo; Lee, Sang Ho; Lee, Bong Yong; Kim, Tae Hwan; Kim, Min Gi; Yoo, Sun Dong
• Is Part Of: Journal of pharmacy and pharmacology. Volume 67:Number 11(2015:Nov.)
• Page Start: 1519
• Page End: 1527
• Publication Date: 2015-08-10
• Subjects: ELISA -- epidermal growth factor -- pharmacokinetics -- systemic exposure -- tissue distribution; Pharmacy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/jphp.12464
• Languages: English
• ISSNs: 0022-3573

Abstract

Abstract: Objectives: This study was conducted to examine the tissue distribution of human recombinant epidermal growth factor (EGF) after multiple intravenous and subcutaneous injections in mice. Methods: Male BALB/c mice were divided into (1) EGF 1 mg/kg intravenous dose, (2) EGF 5 mg/kg intravenous dose, (3) drug-free intravenous control, (4) EGF 1 mg/kg subcutaneous dose, (5) EGF 5 mg/kg subcutaneous dose and (6) drug-free subcutaneous control groups. EGF and drug-free dosing solutions were injected by intravenous and subcutaneous injections once a day for 3 days. EGF concentrations in serum and tissues of kidney, liver, lung, small intestine and tongue were determined by ELISA. Key findings: As the intravenous and subcutaneous doses were increased from 1 to 5 mg/kg, serum Cmax and area under the concentration–time curve (AUC) values were increased dose-proportionally. In lung, tongue and small intestine, increases in AUC were dose-proportional after intravenous injections, but greater than dose-proportional after subcutaneous injections. The fold-increases in Cmax and AUC values were lowest in liver and highest in kidney. Conclusion: Based on Cmax and AUC data, the systemic exposure achieved by subcutaneous injections was comparable with that achieved by intravenous injections.